The 7 major post menopausal osteoporosis markets reached a value of US$ 3.3 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 5.0 Billion by 2034, exhibiting a growth rate (CAGR) of 4.73% during 2023-2034.
The post-menopausal osteoporosis market has been comprehensively analyzed in this report titled "Post Menopausal Osteoporosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post menopausal osteoporosis is a type of osteoporosis that develops in women after menopause. Osteoporosis is a condition characterized by low bone density and structural deterioration of bone tissue, leading to increased fragility as well as a higher risk of fractures. Post menopausal osteoporosis often does not cause noticeable symptoms until a fracture occurs. However, some common indications may be present, including back pain, loss of height over time, a stooped posture (kyphosis), greater susceptibility to fractures, particularly in the wrist, hip, and spine, etc. In many cases, fractures can occur with minimal trauma or even during routine daily activities. The diagnosis of post menopausal osteoporosis typically involves a combination of clinical assessment and diagnostic tests. Healthcare professionals evaluate the patient's medical history, risk factors, and symptoms to determine the likelihood of osteoporosis. Dual-energy X-ray absorptiometry (DXA) is the most commonly used test to measure bone mineral density (BMD) and diagnose osteoporosis. Numerous additional procedures, such as laboratory blood tests and vertebral imaging, may be done to rule out other causes and assess fracture risk.
The escalating cases of decline in estrogen levels during menopause that result in an imbalance between bone formation and bone resorption, thereby leading to a net loss of bone density, are primarily driving the post menopausal osteoporosis market. Furthermore, the rising incidence of several associated risk factors, including genetic predisposition, inadequate intake of calcium and vitamin D, lack of physical activity, prolonged use of corticosteroids, excessive alcohol consumption, etc., is also bolstering market growth. In addition to this, the widespread adoption of oral bisphosphonates, such as alendronate and risedronate, to inhibit bone resorption and reduce the likelihood of fractures in patients is creating a positive outlook for the market. Moreover, the rising utilization of novel sequential therapies involving the use of anabolic agents like teriparatide followed by antiresorptive medications for optimizing bone formation and reducing bone loss is acting as another significant growth-inducing factor. Additionally, the emerging popularity of the trabecular bone score (TBS) imaging technique, since it assesses the microarchitecture of trabecular bone and provides additional information about bone quality, fracture risk, and treatment response, is expected to drive the post menopausal osteoporosis market in the coming years.
This report provides an exhaustive analysis of the post-menopausal osteoporosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post menopausal osteoporosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post menopausal osteoporosis market in any manner.
The post-menopausal osteoporosis market has been comprehensively analyzed in this report titled "Post Menopausal Osteoporosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Post menopausal osteoporosis is a type of osteoporosis that develops in women after menopause. Osteoporosis is a condition characterized by low bone density and structural deterioration of bone tissue, leading to increased fragility as well as a higher risk of fractures. Post menopausal osteoporosis often does not cause noticeable symptoms until a fracture occurs. However, some common indications may be present, including back pain, loss of height over time, a stooped posture (kyphosis), greater susceptibility to fractures, particularly in the wrist, hip, and spine, etc. In many cases, fractures can occur with minimal trauma or even during routine daily activities. The diagnosis of post menopausal osteoporosis typically involves a combination of clinical assessment and diagnostic tests. Healthcare professionals evaluate the patient's medical history, risk factors, and symptoms to determine the likelihood of osteoporosis. Dual-energy X-ray absorptiometry (DXA) is the most commonly used test to measure bone mineral density (BMD) and diagnose osteoporosis. Numerous additional procedures, such as laboratory blood tests and vertebral imaging, may be done to rule out other causes and assess fracture risk.
The escalating cases of decline in estrogen levels during menopause that result in an imbalance between bone formation and bone resorption, thereby leading to a net loss of bone density, are primarily driving the post menopausal osteoporosis market. Furthermore, the rising incidence of several associated risk factors, including genetic predisposition, inadequate intake of calcium and vitamin D, lack of physical activity, prolonged use of corticosteroids, excessive alcohol consumption, etc., is also bolstering market growth. In addition to this, the widespread adoption of oral bisphosphonates, such as alendronate and risedronate, to inhibit bone resorption and reduce the likelihood of fractures in patients is creating a positive outlook for the market. Moreover, the rising utilization of novel sequential therapies involving the use of anabolic agents like teriparatide followed by antiresorptive medications for optimizing bone formation and reducing bone loss is acting as another significant growth-inducing factor. Additionally, the emerging popularity of the trabecular bone score (TBS) imaging technique, since it assesses the microarchitecture of trabecular bone and provides additional information about bone quality, fracture risk, and treatment response, is expected to drive the post menopausal osteoporosis market in the coming years.
This report provides an exhaustive analysis of the post-menopausal osteoporosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for post menopausal osteoporosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post menopausal osteoporosis market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the post menopausal osteoporosis market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the post menopausal osteoporosis market
Competitive Landscape:
This report also provides a detailed analysis of the current post menopausal osteoporosis marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the post menopausal osteoporosis market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the post menopausal osteoporosis market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the post menopausal osteoporosis market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of post menopausal osteoporosis across the seven major markets?
- What is the number of prevalent cases (2018-2034) of post menopausal osteoporosis by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of post menopausal osteoporosis by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with post menopausal osteoporosis across the seven major markets?
- What is the size of the post menopausal osteoporosis patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of post menopausal osteoporosis?
- What will be the growth rate of patients across the seven major markets?
Post Menopausal Osteoporosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for post menopausal osteoporosis drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post menopausal osteoporosis market?
- What are the key regulatory events related to the post menopausal osteoporosis market?
- What is the structure of clinical trial landscape by status related to the post menopausal osteoporosis market?
- What is the structure of clinical trial landscape by phase related to the post menopausal osteoporosis market?
- What is the structure of clinical trial landscape by route of administration related to the post menopausal osteoporosis market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Post Menopausal Osteoporosis - Unmet Needs10 Post Menopausal Osteoporosis - Key Endpoints of Treatment13. Post Menopausal Osteoporosis - Attribute Analysis of Key Marketed and Pipeline Drugs16 Post Menopausal Osteoporosis - Recent Events and Inputs From Key Opinion Leaders18 Post Menopausal Osteoporosis Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Post Menopausal Osteoporosis - Introduction
5 Post Menopausal Osteoporosis - Disease Overview
7 Post Menopausal Osteoporosis - Epidemiology and Patient Population
8 Post Menopausal Osteoporosis - Treatment Algorithm, Guidelines, and Medical Practices
11 Post Menopausal Osteoporosis - Marketed Products
12 Post Menopausal Osteoporosis - Pipeline Drugs
14. Post Menopausal Osteoporosis - Clinical Trial Landscape
15 Post Menopausal Osteoporosis - Market Scenario
17 Post Menopausal Osteoporosis Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.3 Billion |
| Forecasted Market Value ( USD | $ 5 Billion |
| Compound Annual Growth Rate | 3.8% |
| Regions Covered | Global |
